Latest filings (excl ownership)
8-K
Regulation FD Disclosure
10 Jun 24
8-K
Material Modifications to Rights of Security Holders
24 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
2 May 24
8-K
Regulation FD Disclosure
15 Apr 24
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
PRE 14A
Preliminary proxy
28 Mar 24
8-K
Unregistered Sales of Equity Securities
26 Mar 24
S-8
Registration of securities for employees
12 Mar 24
S-3ASR
Automatic shelf registration
12 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
12 Mar 24
8-K
Other Events
4 Jan 24
424B5
Prospectus supplement for primary offering
4 Jan 24
S-3MEF
Registration of additional securities for an S-3
3 Jan 24
424B5
Prospectus supplement for primary offering
2 Jan 24
8-K
Results of Operations and Financial Condition
2 Jan 24
8-K
Regulation FD Disclosure
2 Jan 24
8-K
Regulation FD Disclosure
29 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2 Nov 23
8-K
Regulation FD Disclosure
11 Oct 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Sep 23
8-K
Enrolled 52 participants with Developmental and Epileptic Encephalopathies (DEEs) into the PACIFIC Study
23 Aug 23
EFFECT
Notice of effectiveness
14 Aug 23
CORRESP
Correspondence with SEC
9 Aug 23
UPLOAD
Letter from SEC
8 Aug 23
8-K
Other Events
4 Aug 23
424B5
Prospectus supplement for primary offering
4 Aug 23
S-3
Shelf registration
4 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
26 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
9 May 23
DEFA14A
Additional proxy soliciting materials
11 Apr 23
DEF 14A
Definitive proxy
11 Apr 23
ARS
2022 FY
Annual report to shareholders
11 Apr 23
Latest ownership filings
4
PAUL J SEKHRI
24 May 24
4
PHILLIP M SCHNEIDER
24 May 24
4
Casey Lynch
24 May 24
4
Goff Corinne Le
24 May 24
4
Vincent Aurentz
24 May 24
SC 13G/A
FMR LLC
11 Mar 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
HBM Healthcare Investments (Cayman) Ltd.
13 Feb 24
SC 13G/A
Prosight Management, LP
13 Feb 24
4
Randall Kaye
9 Feb 24
4
Brandi Roberts
9 Feb 24
4
Kevin Robert Lind
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
Farallon Capital Partners, L.P.
30 Jan 24
SC 13D/A
PFIZER INC
29 Jan 24
4
Change in insider ownership
29 Jan 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
26 Jan 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
12 Jan 24
SC 13D/A
PFIZER INC
10 Jan 24
SC 13G/A
FMR LLC
13 Nov 23
4
Jane Tiller
26 May 23
4
PAUL J SEKHRI
26 May 23
4
PHILLIP M SCHNEIDER
26 May 23
4
Casey Lynch
26 May 23
4
Goff Corinne Le
26 May 23
4
Vincent Aurentz
26 May 23
SC 13G
Prosight Management, LP
19 Apr 23
SC 13D/A
PFIZER INC
27 Mar 23
SC 13G/A
FMR LLC
10 Mar 23
SC 13G/A
HBM Healthcare Investments (Cayman) Ltd.
14 Feb 23
SC 13G/A
Cormorant Asset Management, LP
14 Feb 23
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 23
SC 13G
Point72 Asset Management, L.P.
14 Feb 23
4
Brandi Roberts
10 Feb 23
4
Randall Kaye
10 Feb 23
4
Kevin Robert Lind
10 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G/A
Farallon Capital Partners, L.P.
3 Feb 23